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Background: A large proportion of women with breast cancer (BC) are elderly. However, there is a lack of
information regarding BC prognostic factors and care in this population. The aims of this study were to assess the
prognostic factors of relative survival (RS) among women with BC aged ≥ 75 years old and to identify the
predictive factors of treatments administered to this population.
Methods: A population-based study was performed using data from the Cote d’Or breast and gynaecological
cancer registry. Women aged 75 years and older with primary invasive BC and resident in Cote d’Or at the time of
diagnosis made between January 1998 and December 2008 were retrospectively selected. Prognostic factors of RS
were estimated in a generalized linear model with a Poisson error structure. RS rate for the whole population was
given at 5 years. Logistic regression models were used to identify the predictors of the treatments administered.
Results: Six hundred and eighty-one women were included. Median age at diagnosis was 80. Comorbidities
(p=0.02), pT stage (p=0.04), metastases (p=<0.001), having a family doctor (p=0.03) and hormone-receptor status
(p=0.006) were independent prognostic factors of RS. The RS rate at 5 years for the whole population was 78.2%,
95%CI = [72.2-83.0]. Age, pT stage, metastases, histoprognostic SBR grade, hormone receptor status and
comorbidities were frequently found to be predictors of treatment with surgery alone, hormone therapy alone,
breast conserving surgery plus adjuvant therapy and mastectomy plus adjuvant therapy.
Conclusions: Comorbid conditions adversely affect survival in older women with breast cancer. Moreover the
results of this study showed that there are numerous predictors of the type of treatment administered, and that the
most important were age and comorbidities.
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Breast cancer (BC) is the most common malignancy in
women in France [1-4]. With the aging population and
the increase in life expectancy, cancer in elderly people
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reproduction in any medium, provided the orMany studies have reported data about the prognostic
factors of survival among women with BC [5,6]. Despite
improved knowledge of these prognostic factors, there are
no data about the prognostic factors of relative survival
(RS) among older women with BC in a whole population.
The treatment strategy for BC is based on the initial
stage of the tumour, the patient’s age, general health,
tumour histology and prognostic factors [7]. Progress
made in the diagnosis and therapeutic management of
BC [8-10] has led to improvements in prognosis and
overall quality of survival [11]. However, elderly women
with BC are currently undertreated in comparison with
the youngest, and this leads to a considerable decreasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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approaches in older women are most often empiric.
Therapeutic decisions are based on wishful thinking on
behalf of patients and their loved ones and on the clini-
cian’s impressions [15-18]. Moreover, 12% of patients
with BC aged ≥ 80 years old do not receive treatment
and 44% do not undergo surgery. Older women are also
less likely to receive treatment in compliance with guide-
lines [19]. In addition, comorbidities, which are particu-
larly common among older women, complicated the
management of cancer treatment [20].
Contrary to a long-standing belief, BC can be as ag-
gressive in elderly patients as in younger women. Conse-
quently, the management of older patients with BC
should not differ from that in young patients. However,
the predictors of treatment in the elderly have not yet
been clearly assessed [13,14].
Cancer registries provide a unique opportunity to as-
sess survival and to evaluate the predictors of treatments
given in routine practice in this population on compre-
hensive population-based data.
The first aim of this study was to assess the prognostic
factors of RS among women with BC aged ≥ 75 years.
The secondary purpose was to identify the predictors of
treatment in this population.
Methods
Population
A population-based study was undertaken using data from
the Cote d’Or breast and gynaecological cancer registry.
This registry is the only one in France that focuses on
breast and gynaecological cancers. It has been collecting
comprehensive population-based data since 1982. Women
aged 75 years and older with primary invasive BC and res-
iding in Cote d’Or at the time of diagnosis made between
January 1998 and December 2008 were retrospectively
selected. Women lost at the date of diagnosis were
excluded. For patients with synchronous bilateral BC, the
most advanced tumour according to the number of positive
nodes, the tumour size, the Scarff, Bloom, and Richardson
(SBR) grade, and the tumour histology was included.
Studied variables and end points
All patients were staged according to the TNM system
[21]. We considered the pathologic TNM (pTNM) clas-
sification or, when absent, the clinical TNM (cTNM)
classification. We used the cTNM for the predictors of
treatments because the categories of treatments included
surgery or other exclusive treatments without surgery;
the pTNM could therefore not be used, and for the
prognostic factors we used the pTNM, replaced by the
cTNM when the patients were not treated with surgery.
Age at diagnosis was categorized into three classes: 75-79
years, 80-84 years and ≥ 85 years. Pathological tumour sizeand the number of removed and positive nodes were also
recorded. Removed nodes were categorized into two classes:
≤ 10 nodes and > 10 nodes and positive nodes into three
classes: 0, 1-3 and ≥ 4 nodes. Tumour characteristics, such
as SBR grade classified as grades 1+2 or grade 3, and hor-
mone receptor status, considered positive when oestrogen
and/or progesterone were positive, were also collected. Clin-
ical and demographic data, such as the circumstances of
diagnosis (clinical diagnosis or individual screening), the
matrimonial status (single or not), having a family doctor
(yes or no), the vital status (dead or alive) and the place of
residence (rural or urban) were recorded too. The comor-
bidities were collected at the diagnosis, as were all of the dis-
eases associated with BC at the time of diagnosis: diabetes,
high blood pressure, neurological disease (Alzheimer, Par-
kinson, epilepsy), psychiatric illness, tuberculosis, thyroid
disorder, genetic abnormalities and previous history of dis-
ease affecting treatment administration. Comorbidities were
classified in two categories: at least one comorbidity and
no comorbidity. The period of diagnosis was split into
two: 1998-2003 and 2004-2008 according to the median
of distribution. Treatments were grouped into exclusive
categories: surgery alone, hormone therapy alone, breast-
conserving surgery plus adjuvant therapy (BCS plus adju-
vant therapy) and mastectomy plus adjuvant therapy.
Patients without treatment constituted the “no treatment”
category, and the “others” category was used for the follow-
ing exclusive treatments: chemotherapy alone, radiotherapy
alone, chemotherapy plus hormone therapy, chemotherapy
plus radiotherapy, radiotherapy plus hormone therapy,
chemotherapy plus radiotherapy plus hormone therapy,
neoadjuvant chemotherapy plus surgery plus adjuvant
therapy and neoadjuvant chemotherapy plus surgery.
Survival was calculated from the date of diagnosis until
the date of death or the date of last follow-up. The cut-off
date for the survival analysis was set at 01 January 2010.
Patients who were alive after the cut-off date were censored.
Statistical methods
Quantitative variables are given as means, standard
deviations (SD), medians and ranges, while qualitative
variables are given as percentages. The percentage of
missing values is also provided.
Treatments categories were compared according to
the follow-up periods using Chi2 tests. Cochran-
Armitage trend tests were used to compare treatments
according to the age classes.
RS rate with the 95% confidence interval (CI) for the
whole population was given at 5 years. RS is an estima-
tor of the excess mortality ratio (EMR) estimated from
life tables as the ratio of the observed survival of the
patients (where all deaths are considered events) to the
expected survival (ES) [22]. The ES was estimated using
Cote d’Or female life-expectancy tables stratified by age
Table 1 Characteristics of patients (N=681) and tumours
Variables N (681) % Mean (SD) Median
[min;max]
Age at diagnosis (years) 681 81.3 (5.2) 80.0 [75;98]
Pathological tumor size (mm) 546 27.0 (19.8) 22.0 [2;160]
Nodes removed 612 8.2 (6.3) 8.0 [0;32]
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Not single 183 26.9
Single‡ 288 42.3
Unknown 210 30.8








Abbreviations: N = number of patients; % = percentage; SD = standard
deviations. *Patients without surgery;
†For patients without surgery pTNM stage was replaced by TNM; ‡Patient
single, divorced or widowed.
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mated in a generalized linear model with a Poisson error
structure [23]. Follow-up time was stratified in annual
intervals. Prognostic factors of survival were assessed
using univariate and multivariate analyses of RS.
Univariate and multivariate logistic regression models
were performed to identify the predictive factors of the
administration of the different type of exclusive treat-
ments: surgery alone, hormone therapy alone, BCS plus
adjuvant therapy alone and mastectomy plus adjuvant
therapy alone. Odds Ratios (OR) and their 95% confi-
dence intervals (CI) are given.
For RS and logistic regression, all variables with a uni-
variate p-value ≤ 0.20 were eligible for multivariate ana-
lyses. Correlations and interactions were tested for
eligible variables. To prevent co-linearity, when two vari-
ables were significantly correlated, one variable was
retained according to its clinical relevance or to the
value of the likelihood ratio. All reported p values are
two sided. The statistical significance level was set at
p<0.05. Analyses were done using SAS (Statistical Ana-
lysis system version 9.2) and or STATA (version 9.0).
Ethics statement
The Breast and Gynaecologic Cancer Registry of Cote
d’Or was approved by the CNIL (National Commission
on Informatics and Liberties) for the collection and
recording data for research purposes (authorization
number DR-2012-038).Results
Patients’ characteristics
Seven hundred and fifteen (715) women aged 75 years and
older with invasive primary BC were registered from Janu-
ary 1998 to December 2008. Among them, 34 were lost to
follow-up at the date of diagnosis. Finally, 681 patients were
included in the study. The median age at diagnosis was 80
(range, 75 to 98 years). The clinical and pathological fea-
tures of the studied population are summarized in Table 1.
Information on comorbidities was missing for 14.5% of
the women. The comorbidities recorded were: high blood
pressure (27%), diabetes (5.4%), neurological disease (3%),
obesity (1.2%), psychiatric illness (1%), tuberculosis (1.5%),
thyroid disorder (4%), previous history of stroke, heart fail-
ure or thrombosis (8%), and previous history of disease
affecting treatment administration (10%).
Treatment description
Concerning treatment, 52 (7.6%) underwent surgery alone,
and hormone therapy alone was given to 74 (10.9%). BCS
plus adjuvant therapy was given to 238 (34.9) while 211
patients (31%) received mastectomy plus adjuvant therapy.
Nineteen (2.8%) did not receive treatment and 26 patients
(3.8%) were treated by other treatments: chemotherapy
alone or radiotherapy alone or chemotherapy plus hormone
therapy or chemotherapy plus radiotherapy or radiotherapy
plus hormone therapy or chemotherapy plus radiotherapy
plus hormone therapy or neoadjuvant chemotherapy plus
surgery plus adjuvant therapy or neoadjuvant chemother-
apy plus surgery. For 1998-2003 and 2004-2008, the use of
BCS plus adjuvant therapy (p=0.63), mastectomy plus adju-
vant therapy (p=0.52) and other treatments (p=0.43) was
similar. In contrast, patients were less often treated by sur-
gery alone in the second period (p<0.001): 11.2% and 4.4%
for 1998-2003 and 2004-2008, respectively. The use of hor-
mone therapy alone was more frequent in the second
period (p=0.001): 6.5% and 14.7%, respectively (Table 2).
Older patients were more likely to be treated with sur-
gery alone (p=0.02) and with hormone therapy alone
(p<0.001) and were more likely to receive no treatment
(p=0.006). BCS plus adjuvant therapy (p<0.001) and other
treatments (p=0.03) were less likely to be given to older
patients. In contrast, the use of mastectomy plus adjuvant
therapy did not vary with age (p=0.40) (Table 3).
Prognostic factors and analyses of RS
The median follow-up was 3 years (min-max) = (0.01-
11.96). At the cut-off, 305 deaths (45%) had occurred.
RS rates decreased with follow-up. RS at 1 year for the
whole population was 93.5%, 95% CI = [90.5-95.5] and
at 5 years was 78.2%, 95% CI = [72.2-83.0].
In the multivariate analysis, the pathological tumor
size correlated with the pT stage, and we therefore
retained the pT stage for the analyses. Examined and
Table 2 Treatment description by period
Period 1998-2003 (N= 321) 2004-2008 (N=360) p value* All cases (N=681)
Treatments 321 % 360 % 681 %
No treatment 0.65
Yes 10 3.1 9 2.5 19 2.8
No 306 95.3 340 94.4 646 94.9
Unknown 5 1.6 11 3.1 16 2.3
Surgery alone <0.001
Yes 36 11.2 16 4.4 52 7.6
No 254 79.1 328 91.1 582 85.5
Unknown 31 9.7 16 4.4 47 6.9
Hormone therapy 0.001
Yes 21 6.5 53 14.7 74 10.9
No 264 82.2 282 78.3 546 80.2
Unknown 36 11.2 25 6.9 61 9.0
Breast conserving surgery plus adjuvant therapy 0.63
Yes 113 35.2 125 34.7 238 34.9
No 193 60.1 231 64.2 424 62.3
Unknown 15 4.7 4 1.1 19 2.8
Mastectomy plus adjuvant therapy 0.52
Yes 95 29.6 116 32.2 211 31.0
No 210 65.4 230 63.9 440 64.6
Unknown 16 5.0 14 3.9 30 4.4
Others† 0.43
Yes 10 3.1 16 4.4 26 3.8
No 275 85.7 319 88.6 594 87.2
Unknown 36 11.2 25 6.9 61 9.0
Abbreviations: N = number of patients.
*Chi 2 test.
†Others: chemotherapy alone, radiotherapy alone, chemotherapy plus hormone therapy, chemotherapy plus radiotherapy, radiotherapy plus hormone therapy,
chemotherapy plus radiotherapy plus hormone therapy, neoadjuvant chemotherapy plus surgery plus adjuvant therapy, neoadjuvant chemotherapy plus surgery.
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stage, respectively, and we retained the clinical N stage
and pN stage for the analyses.
Multivariate RS analyses revealed an increased risk of
death in patients with an advanced pT stage: Relative Ex-
cess Rates (RER) =2.58, 95% CI = [1.23-5.42], in patients
with metastasis at the time of diagnosis: RER=6.86, 95%
CI = [3.43-13.73] and in patients with comorbidities:
RER=2.35, 95% CI = [1.03-5.36]. In contrast, a decreased
risk of death was observed in patients who had a family
doctor: RER=0.22, 95% CI = [0.07-0.68] and in patients
with hormone-receptor positive tumours: RER=0.33,
95% CI = [0.16-0.70] (Table 4).
Predictive factors of treatments administered
Predictors of the treatments are listed in Table 5.
Patients with hormone-receptor positive tumours or
patients diagnosed in the period from 2004 to 2008 were
less likely to undergo surgery alone. OR were 0.29, 95%CI = [0.12-0.72], and 0.40, 95% CI = [0.20-0.78], respect-
ively. Older patients with metastasis did not receive sur-
gery alone. The oldest patients (≥85 years), patients with
metastasis or with comorbidities were more often trea-
ted with hormone therapy alone. The oldest patients
(80-84 and ≥85 years) or patients with advanced
tumours (stages T2 and T3+T4) were less likely to re-
ceive BCS plus adjuvant therapy. In contrast, patients
with advanced tumours (stages T2 and T3+T4) were
more likely to be treated with mastectomy plus adjuvant
therapy, OR were 5.57, 95% CI = [3.09-10.03] and 3.60,
95%CI = [1.78-7.29], respectively. Patients with histo-
prognostic SBR grade 3 were more likely to be treated
with mastectomy plus adjuvant therapy, OR= 2.18, 95%
CI = [1.26-3.76]. Moreover, there were interactions be-
tween age and the circumstances of diagnosis for the
predictors of mastectomy plus adjuvant therapy
(p<0.001). Indeed, patients aged ≥ 85 years with a clin-
ical diagnosis were 74% less likely to be treated with
Table 3 Treatment description by age
Age 75-79 (N=310) 80-84 (N=208) ≥85 (N=163) p value* All cases (N=681)
Treatments 310 % 208 % 163 % 681 %
No treatment 0.006
Yes 4 1.3 6 2.9 9 5.5 19 2.8
No 304 98.1 197 94.7 145 89.0 646 94.9
Unknown 2 0.6 5 2.4 9 5.5 16 2.3
Surgery alone 0.02
Yes 19 6.1 13 6.3 20 12.3 52 7.6
No 272 87.7 184 88.5 126 77.3 582 85.5
Unknown 19 6.1 11 5.3 17 10.4 634 93.1
Hormone therapy <0.001
Yes 12 3.9 18 8.7 44 27.0 74 10.9
No 277 89.4 176 84.6 93 57.1 546 80.2
Unknown 21 6.8 14 6.7 26 16.0 61 9.0
Breast conserving surgery plusadjuvant therapy <0.001
Yes 144 46.5 69 33.2 25 15.3 238 34.9
No 157 50.6 135 64.9 132 81.0 424 62.3
Unknown 9 2.9 4 1.9 6 3.7 19 2.8
Mastectomy plus adjuvant therapy 0.40
Yes 92 29.7 83 39.9 36 22.1 211 31.0
No 208 67.1 116 55.8 116 71.2 440 64.6
Unknown 10 3.2 9 4.3 11 6.7 30 4.4
Others† 0.03
Yes 18 5.8 5 2.4 3 1.8 26 3.8
No 271 87.4 189 90.9 134 82.2 594 87.2
Unknown 21 6.8 14 6.7 26 16.0 61 9.0
Abbreviations: N = number of patients.
*Cochran-Armitage trend test.
†Others: chemotherapy alone, radiotherapy alone, chemotherapy plus hormone therapy, chemotherapy plus radiotherapy, radiotherapy plus hormone therapy,
chemotherapy plus radiotherapy plus hormone therapy, neoadjuvant chemotherapy plus surgery plus adjuvant therapy, neoadjuvant chemotherapy plus surgery.
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between 75 and 79 years old with a clinical diagnosis.
Discussion
The results of this study showed that tumours were dis-
covered at an advanced stage in elderly patients. Nine
per cent of patients had metastatic tumours and 9.4%
had inflammatory tumours or tumours with extension to
the skin or to the chest wall.
According to the follow-up period, older patients were
less likely to be treated with surgery alone and more likely
to receive hormone therapy alone in the more recent
period. These results are in line with a study conducted by
Bastiaannet et al, which showed that patients aged ≥ 75
years were less likely to undergo surgery and more likely
to have hormone therapy [24]. One possible explanation
could be that more recently surgery alone was not pro-
posed to treat BC because with the improvement in breastcancer management other, more effective treatments like
hormone therapy or treatment combinations have been
preferred to surgery alone to treat older women with BC.
Other explanations could be that elderly women with BC
are too frail and have more advanced tumours associated
with the presence of comorbidities.
Regarding the assessment of RS, the analyses were done
on comprehensive data. Moreover, in this population-
based study, the follow-up for vital status was complete
for all included patients with no patients lost to follow-up
at the cut-off date. Our multivariate analyses of RS showed
that pT stage, metastasis, having a family doctor, hormone
receptor status and comorbidities were independent pre-
dictors of the length of survival. pT stage, metastasis and
hormone receptor status have already been shown to be
prognostic factors of survival in BC patients [6]. Indeed,
the influence of hormone receptors could be attributed to
the efficacy of hormone therapy given to patients with
Table 4 Prognostic factors for relative survival
Factors N=(681) Number of deaths Univariate analysis Multivariate analysis (N=495)
RER 95% CI p value RER 95% CI p value
Age 681 0.001 0.18
75-79 310 107 1 1
80-84 208 88 0.99 0.52-1.88 1.01 0.47-2.16
≥85 163 110 2.75 1.68-4.48 2.15 1.02-4.55
pT stage 658 <0.001 0.04
pT0+pT1 283 91 0.53 0.24-1.17 1.77 0.72-4.36
pT2 245 109 1 1
Pt3+Pt4 130 89 3.89 2.20-6.82 2.58 1.23-5.42
pN stage 619 <0.001 0.14
pN0 350 132 1 1
pN+ 269 135 3.13 1.68-5.75 1.75 0.80-3.83
pM stage 640 <0.001 <0.001
pM0 576 227 1 1
pM1 64 47 10.18 6.11-16.95 6.86 3.43-13.73
Having a family doctor 672 <0.001 0.03
No 51 41 1 1
Yes 621 258 0.17 0.11-0.28 0.22 0.07-0.68
Histoprognostic SBR grade 642 <0.001 0.08
1+2 482 185 1 1
3 160 93 2.73 1.66-4.51 1.87 0.93-3.79
Hormone receptors 670 <0.001 0.006
Negative 80 46 1 1
Positive 590 255 0.38 0.23-0.63 0.33 0.16-0.70
Comorbidities 582 0.03 0.02
No 163 51 1 1
Yes 419 179 4.26 1.13-16.28 2.35 1.03-5.36
Diagnosis circumstances 580 0.10 0.13
Clinic 471 209 1 1
Individual screening 109 27 0.13 0.01-1.48 0.42 0.11-1.65
Place of residence 677 0.43
Rural 203 92 1
Urban 474 211 0.82 0.50-1.35
Period 681 0.79
1998-2003 321 190 1
2004-2008 360 115 1.07 0.66-1.73
Matrimonial status 471 0.89
Single* 288 131 1
Not single 183 73 0.96 0.53-1.75
Abbreviations: RER = relative excess rates; CI = confidence interval, N = number of patients.
* Patient single, divorced or widowed.
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showed that comorbidities had a significant impact on sur-
vival after BC with poorer survival among old patients
with one or more comorbid conditions [25]. Patients whohad a family doctor had a lower risk of death than those
without a family doctor. This could be explained by the
fact that patients who had a family doctor were more
likely to be diagnosed with less advanced BC.
Table 5 Multivariate logistic regression analysis of
predictive factors of treatments administered
Variables OR 95% CI p value














Histoprognostic SBR grade 0.25
1+2 1
3 1.59 0.72-3.49
Place of residence 0.16
Rural 1
Urban 1.84 0.78-4.33
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Individual screening 0.72 0.24-2.13
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Rural 1
Urban 1 0.47-2.12
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Table 5 Multivariate logistic regression analysis of












Not single 0.72 0.44-1.18
Place of residence 0.22
Rural 1
Urban 0.73 0.44-1.20
Age x diagnosis circumstances § <0.001
75-79 x clinical diagnosis 1
80-84 x clinical diagnosis 1.63 0.91-2.93
≥85 x clinical diagnosis 0.26 0.13-0.52
75-79 x individual screening 0.45 0.17-1.18
80-84 x individual screening 0.33 0.09-1.18
≥85 x individual screening 1.25 0.24-6.38
Abbreviations: OR = Odds Ratios; CI = confidence interval, N = number of
patients.
*Predictive factors for surgery alone without the variable M stage because no
patient with stage M1 had surgery alone.
†Predictive factors for BCS plus adjuvant therapy without the variable M stage
because only 4 patients with stage M1 received BCS plus adjuvant therapy.
‡patient single, divorced or widowed.
§Interaction age and diagnosis circumstances.
NB: Multivariate logistic regression analyses were adjusted for age, TNM stage,
period, diagnosis circumstances, comorbidities, histoprognostic SBR grade,
tumour type, hormone receptors, matrimonial status, and place of residence.
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Eurocare-4 study, which analysed survival in cancer
patients diagnosed from 1995 to 1999, showed that 5-year
RS in France was 82.7% [26]. Survival was shorter in our
population than in the whole population of BC patients in
France. This could be due to the characteristics of our
population, which was probably older than the population
studied in Eurocare 4, and had comorbidities.
The results of this study showed that age was the major
predictor of the type of treatment administered. The pro-
portion of patients who had no treatment increased with
age. Moreover, except for surgery and mastectomy plus
adjuvant therapy, upon which age had no influence, the
oldest patients were more often treated with hormone
therapy and less likely to be treated with BCS plus adju-
vant therapy, probably because of advanced stage of the
tumour at discovery and the presence of comorbiditiesthat preclude treatment with BCS in the elderly. These
results are in line with those reported in other studies
[27,28]. Adjuvant therapy (radiotherapy) after primary sur-
gery was less frequent in the oldest age group with BC.
This was not the case for hormone therapy, which was
more likely to be administered in the oldest patients than
in patients in the youngest age group.
According to the characteristics of the tumour, older
patients with an advanced tumour (stage T2, T3+T4) were
more likely to undergo mastectomy plus adjuvant therapy
and less likely to have BCS plus adjuvant therapy. This
could be due to large tumour size which precludes BCS.
Treatment with mastectomy plus adjuvant therapy limits
organ invasion and thus decreases the risk of disease re-
currence in the breast or distant metastasis. Another ex-
planation could be the choice of the physician to avoid
adjuvant radiotherapy for extremely frail women. Never-
theless, patients with hormone-receptor positive tumours
were less often treated with surgery alone because these
patients were usually treated with hormone therapy in ac-
cordance with the guidelines of the French health author-
ities [29]. Patients with metastasis were also more likely to
receive hormone therapy, but less often treated with sur-
gery. Surgery is a local treatment and is thus inadequate
for the treatment of metastatic disease. Patients with
comorbidities were more often treated with hormone
therapy. Older patients with comorbidity received less ag-
gressive treatments as shown in another study [28]. Treat-
ments are often modified according to age-related issues
such as comorbidity and the general state of health. This
highlights the importance of considering comorbidities in
the management of BC.
The strength of this study is that the analyses were done
in a heterogeneous and exhaustive group of patients, using
data from the Cote d’Or breast and gynaecological cancer
registry. Therefore, the results could be considered repre-
sentative of elderly patients living in the department during
this period. Cancer registries provide the unique opportun-
ity to evaluate predictors of treatments given in routine
practice and to assess survival using comprehensive
population-based data. The use of RS makes it possible to
correct for non-BC-related deaths while circumventing the
problems associated with establishing the cause of death.Conclusions
Comorbidity was associated with decreased survival in
older women with breast cancer. Moreover, the results
of this study showed that there are numerous predictors
of the type of treatment administered, of which the most
important were age and comorbidities.
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